AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31863227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 493
Study 31863227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 31863227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (CR or PR patients)
Number of subjects: 493
Study 30266356 — intervention group
Group type: EXPERIMENTAL
Intervention: CGuard™ stent
Number of subjects: 58
Study 30266356 — intervention group
Group type: COMPARATOR
Intervention: Wallstent™
Number of subjects: 58
Study 30266356 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B neurobiomarker
Number of subjects: 58
Study 30410142 — intervention group
Group type: EXPERIMENTAL
Intervention: Transspinous decompressive laminectomy
Number of subjects: 82
Study 26851686 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma disc decompression (PDD)
Number of subjects: 177
Study 26851686 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 177
Study 24668359 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Group using 'Wii Fit Plus' in standing
Number of subjects: 30
Study 24668359 — intervention group
Group type: COMPARATOR
Intervention: Upper Limb Group using 'Wii Sports/Sports Resort' in sitting
Number of subjects: 30
Study 22197474 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 6 mg
Number of subjects: 254
Study 22197474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 20460116 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysically-anchored noxious temperature
Number of subjects: 18
Study 20460116 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state PAFs
Number of subjects: 18
Study 17594219 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused history and physical exam scripts
Number of subjects: 0
Study 17594219 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15558726 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental vaginal gel
Number of subjects: 0
Study 15558726 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 15114295 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment with 40 mg of ZnSO4 in a single dose
Number of subjects: 20
Study 15114295 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with 100 mg ZnSO4 in a single dose daily for 7 days
Number of subjects: 20
Study 15114295 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal healthy volunteers)
Number of subjects: 20
Study 10752473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental-worry disclosure condition (writing about dental worries)
Number of subjects: 80
Study 10752473 — intervention group
Group type: COMPARATOR
Intervention: Control condition (writing about previous day's activities)
Number of subjects: 80
Study 10752473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental-worry disclosure condition
Number of subjects: 80
Study 8607302 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms.kg-1 of mivacurium (Group M)
Number of subjects: 30
Study 8607302 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms.kg-1 of mivacurium after 1500 micrograms.kg-1 of succinylcholine (Group SchM)
Number of subjects: 30
Study 2032325 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacuated phlebotomy tube designed for trace metal analysis
Number of subjects: 0
Study 2032325 — intervention group
Group type: COMPARATOR
Intervention: Ultra-clean polystyrene phlebotomy syringes
Number of subjects: 0
Study 2032325 — intervention group
Group type: COMPARATOR
Intervention: Standard evacuated phlebotomy tubes
Number of subjects: 0
Study 31094442 — intervention group
Group type: EXPERIMENTAL
Intervention: High sun protection behaviors (wearing protective clothing, avoiding the sun, using sunscreen)
Number of subjects: 313
Study 28495558 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 50
Study 28495558 — intervention group
Group type: COMPARATOR
Intervention: non-stressful placebo version (PTSST)
Number of subjects: 50
Study 28495558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 50
Study 28495558 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic decisions
Number of subjects: 50
Study 26004659 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT+abstinence-based contingency management (CM)
Number of subjects: 153
Study 26004659 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT+CM+Parent Training (PT)
Number of subjects: 153
Study 26004659 — intervention group
Group type: COMPARATOR
Intervention: Individual MET/CBT
Number of subjects: 153
Study 23237616 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and family tailored interventions to manage asthma symptoms; specific dosage and duration not applicable as this is qualitative data.
Number of subjects: 0
Study 21036617 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the posterior knee capsule (PCS)
Number of subjects: 128
Study 21036617 — intervention group
Group type: COMPARATOR
Intervention: No stripping of the posterior knee capsule (no-PCS)
Number of subjects: 128
Study 19142259 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-Core obturation technique
Number of subjects: 98
Study 19142259 — intervention group
Group type: COMPARATOR
Intervention: Cold lateral compaction
Number of subjects: 98
Study 17695792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Tablets (active treatment for 4 weeks)
Number of subjects: 73
Study 17695792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 73
Study 17695792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Tablets (active treatment for 8 weeks)
Number of subjects: 73
Study 17695792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 73
Study 15217515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic chemotherapy (LC) - subcutaneous injection of 4 ml of carboplatin-activated carbon suspension (20 mg of carboplatin)
Number of subjects: 60
Study 15217515 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy (VC) - intravenous administration of 20 mg of aqueous carboplatin
Number of subjects: 60
Study 15217515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastasis
Number of subjects: 60
Study 11231856 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (500 mg of methylprednisolone administered intravenously 2 hours before surgery)
Number of subjects: 33
Study 11231856 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 9670258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) plus external beam radiotherapy (EBRT) with concomitant chemotherapy (5-FU, leucovorin)
Number of subjects: 63
Study 9670258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) plus external beam radiotherapy (EBRT) alone
Number of subjects: 63
Study 9670258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) plus external beam radiotherapy (EBRT)
Number of subjects: 63
Study 7758398 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (4 g or 2 g) with 10% or 5% glucose infusion
Number of subjects: 60
Study 7758398 — intervention group
Group type: COMPARATOR
Intervention: Control group (10% or 5% glucose infusion without L-carnitine)
Number of subjects: 60
Study 2455778 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with vinblastine for 6 months
Number of subjects: 253
Study 2455778 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 253
Study 2455778 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (cisplatin, vinblastine, and bleomycin)
Number of subjects: 253
Study 2455778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin pulmonary toxicity
Number of subjects: 253
Study 2455778 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelosuppression
Number of subjects: 253
Study 30799192 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin levels <51.4 g/L
Number of subjects: 12621
Study 30799192 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin levels ≥51.4 g/L
Number of subjects: 12621
Study 30799192 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin levels <51.4 g/L without proteinuria
Number of subjects: 12621
Study 30119072 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods used in trials
Number of subjects: 116
Study 30119072 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methodology
Number of subjects: 116
Study 28600024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol plus aspirin
Number of subjects: 53
Study 28600024 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 53
Study 25132320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom®G4 Platinum (DG4P)
Number of subjects: 24
Study 25132320 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Paradigm Veo Enlite system (ENL)
Number of subjects: 24
Study 24189352 — intervention group
Group type: EXPERIMENTAL
Intervention: OS‐1(®)
Number of subjects: 10
Study 24189352 — intervention group
Group type: COMPARATOR
Intervention: Pocari Sweat(®)
Number of subjects: 10
Study 21386732 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Training (BT) for 4 weeks, 3 times per week
Number of subjects: 30
Study 21386732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 19441668 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (n=51, 10-20 mg/day)
Number of subjects: 90
Study 19441668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (n=39, 75-150 mg/day)
Number of subjects: 90
Study 16687967 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus HCTZ
Number of subjects: 872
Study 16687967 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine plus HCTZ
Number of subjects: 872
Study 14728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and compound cyproterone acetate (CPA) (group A3)
Number of subjects: 45
Study 14728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone (group A2)
Number of subjects: 45
Study 14728846 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA alone (group A1)
Number of subjects: 45
Study 14728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and CPA (group A3)
Number of subjects: 45
Study 14728846 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-PCOS infertility patients, group B)
Number of subjects: 45
Study 10775075 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) therapy
Number of subjects: 18
Study 8839730 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated Oka strain varicella vaccine
Number of subjects: 191
Study 1727744 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 230
Study 1727744 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 230
Study 1727744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 6695658 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 7.5 mg intravenously
Number of subjects: 20
Study 6695658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31665017 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 30037480 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letters sent to parents or guardians of eligible adolescents due for the first dose of HPV vaccine.
Number of subjects: 81558
Study 30037480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminder letters sent until December 8, 2015).
Number of subjects: 81558
Study 26995797 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized, comparative local anesthetic blocks
Number of subjects: 4
Study 26995797 — intervention group
Group type: COMPARATOR
Intervention: Randomized, placebo-controlled blocks
Number of subjects: 4
Study 24905296 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily for 6 months
Number of subjects: 48
Study 22920048 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40 mg/25 mg
Number of subjects: 176
Study 22920048 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg daily to OM 40 mg
Number of subjects: 176
Study 22920048 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 176
Study 20519552 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-288034 coadministered with probenecid
Number of subjects: 0
Study 20519552 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-288034 coadministered with cimetidine
Number of subjects: 0
Study 17602170 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry/apple juice providing 97 mg quercetin and 16 mg ascorbic acid a day
Number of subjects: 168
Study 17602170 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry/apple juice intervention
Number of subjects: 168
Study 17602170 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms
Number of subjects: 168
Study 17602170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyp1B1 5 variant genotype
Number of subjects: 168
Study 17602170 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT variants
Number of subjects: 168
Study 17602170 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTT1 variants
Number of subjects: 168
Study 15074091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushen capsule (PSC) (4 capsules, tid)
Number of subjects: 240
Study 15074091 — intervention group
Group type: COMPARATOR
Intervention: Zhibituo tablet (3 tablets, tid)
Number of subjects: 240
Study 11677003 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg, administered three times daily for 12 months)
Number of subjects: 84
Study 11677003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 11677003 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg)
Number of subjects: 84
Study 9704262 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending to red checks
Number of subjects: 0
Study 9704262 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending to blue checks
Number of subjects: 0
Study 9704262 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended stimuli
Number of subjects: 0
Study 9704262 — intervention group
Group type: COMPARATOR
Intervention: Unattended stimuli
Number of subjects: 0
Study 9704262 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-latency attention-sensitive components
Number of subjects: 0
Study 8124798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged dilatations (15 minutes)
Number of subjects: 478
Study 8124798 — intervention group
Group type: COMPARATOR
Intervention: Standard dilatations (1 minute)
Number of subjects: 478
Study 2768768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Number of subjects: 101
Study 2768768 — intervention group
Group type: COMPARATOR
Intervention: Yoga and Flexibility
Number of subjects: 101
Study 2768768 — intervention group
Group type: COMPARATOR
Intervention: Waiting List
Number of subjects: 101
Study 334220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine 100 mg
Number of subjects: 6
Study 334220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine 50 mg
Number of subjects: 6
Study 334220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30606789 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (18 months treatment after initial 6 months)
Number of subjects: 104
Study 30606789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (18 months treatment after initial 6 months)
Number of subjects: 104
Study 30606789 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (42 months total follow-up)
Number of subjects: 104
Study 30606789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (42 months total follow-up)
Number of subjects: 104
Study 29854140 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS program for BMI screening and follow-up
Number of subjects: 33945
Study 27429204 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination within 7 days of birth
Number of subjects: 4224
Study 27429204 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 4224
Study 27429204 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination within 7 days of birth (in children of BCG-vaccinated mothers)
Number of subjects: 4224
Study 24613094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 24613094 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol ≥30 ng/mL with percent mean body weight
Number of subjects: 37
Study 24613094 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin, cortisol, and mental health changes
Number of subjects: 37
Study 22703475 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 756
Study 22703475 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 756
Study 19148403 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints fabricated in maximum intercuspation
Number of subjects: 20
Study 19148403 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splints fabricated in centric relation
Number of subjects: 20
Study 17724676 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 12484
Study 17724676 — intervention group
Group type: COMPARATOR
Intervention: Conventional Papanicolaou (Pap) smear
Number of subjects: 12484
Study 16086878 — intervention group
Group type: EXPERIMENTAL
Intervention: TP group (docetaxol plus cisplatin)
Number of subjects: 43
Study 16086878 — intervention group
Group type: COMPARATOR
Intervention: GP group (gemzar plus cisplatin)
Number of subjects: 43
Study 12411834 — intervention group
Group type: EXPERIMENTAL
Intervention: I NNC 13‐8241
Number of subjects: 19
Study 10572333 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (specific type not mentioned)
Number of subjects: 118
Study 7479228 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. injection of heparin
Number of subjects: 72
Study 7479228 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 1980415 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 206
Study 1980415 — intervention group
Group type: EXPERIMENTAL
Intervention: Promazin (1.0 mg/kg)
Number of subjects: 206
Study 1980415 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazin (1.0 mg/kg)
Number of subjects: 206
Study 1980415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorphenaethazin (1.0 mg/kg)
Number of subjects: 206
Study 1980415 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 206
Study 6992760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 0
Study 6992760 — intervention group
Group type: COMPARATOR
Intervention: Placebo influences
Number of subjects: 0
Study 6992760 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment factors (sex, social class, optimism about therapist)
Number of subjects: 0
Study 6992760 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural course of migraine
Number of subjects: 0
Study 6992760 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of improvement during treatment
Number of subjects: 0
Study 6992760 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of improvement at end of trial
Number of subjects: 0
Study 31124401 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS or voice call reminders at 48 and 24 hours before the postnatal appointment
Number of subjects: 350
Study 31124401 — intervention group
Group type: COMPARATOR
Intervention: Usual notification of appointments provided by health professionals at discharge
Number of subjects: 350
Study 27658914 — intervention group
Group type: EXPERIMENTAL
Intervention: Being Responsible for Ourselves (BRO) physical‐activity intervention consisting of three 90‐min one‐on‐one sessions
Number of subjects: 595
Study 27658914 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 595
Study 25328079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg)
Number of subjects: 25
Study 25328079 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (750 mg)
Number of subjects: 25
Study 24942407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100mg twice daily)
Number of subjects: 100
Study 24942407 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75mg daily)
Number of subjects: 100
Study 22714065 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery clipping and myomectomy (experimental group)
Number of subjects: 166
Study 22714065 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myomectomy only (control group)
Number of subjects: 166
Study 21147691 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg intravenous every 3 months
Number of subjects: 68
Study 21147691 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 68
Study 17991545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg/day for 120 days) plus surgery
Number of subjects: 119
Study 17991545 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 119
Study 17991545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 119
Study 16296363 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3‐4 microg x kg(‐1)
Number of subjects: 40
Study 16296363 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.04‐0.05 mg x kg(‐1)
Number of subjects: 40
Study 11911994 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryltrinitrate (GTN) + Capsaicin cream
Number of subjects: 40
Study 11911994 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin cream alone
Number of subjects: 40
Study 11911994 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 40